$2.00
-0.30-13.04%
Last update: Nov 10, 1:37 PM
Kalaris Therapeutics Inc (KLRS) Stock Price, Quote, News & History
KLRSNASDAQ
Kalaris Therapeutics (NASDAQ: KLRS) stock jumps 18% after releasing expanded Phase 1a data for its AMD treatment, TH103.
You can purchase shares of Kalaris Therapeutics (NASDAQ:KLRS) through any online brokerage.
Other companies in Kalaris Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Kalaris Therapeutics has a consensus price target of $19.60.
The stock price for Kalaris Therapeutics (NASDAQ: KLRS) is $2 last updated November 10, 2026 at 1:37 PM EST.
There are no upcoming dividends for Kalaris Therapeutics.
Kalaris Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Kalaris Therapeutics.
Kalaris Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth...
